Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-006 in malignant solid tumors (phase Ib/II, open-label)
CTR20244651Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2025
- Countries
- 1
01
Overview
A Phase 2 trial of FH-006 in Non-hematologic malignancy, sponsored by Hengrui Therapeutics. Started Jan 2025; status: active.
02
Drugs
FH-006
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20244651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244651.